Liao Guoqing, Wang Hongmei, Qu Yimei, Liu Penghui, Xie Guoqing, Dai Haifeng
Department of Oncology and Hematology, Hospital 309 of PLA, Beijing 100091, P.R.China.
Zhongguo Fei Ai Za Zhi. 2003 Apr 20;6(2):138-40. doi: 10.3779/j.issn.1009-3419.2003.02.13.
To observe the efficacy and safety of navelbine (NVB) combined with ifosfamide (IFO) and cisplatin (DDP) (NIP regimen) and IFO plus DDP (IP regimen) for advanced non-small cell lung cancer (NSCLC).
One hundred and twenty patients with advanced NSCLC pathologically proved were randomly divided into group A (NIP regimen, n=60) and group B (IP regimen, n=60).
In group A, 58 patients were evaluable. The response rates were 58.62%(34/58), 65.58%(17/26) and 53.12% (17/32) in whole group, untreated patients, and retreated patients, respectively. The median duration of survival was 11.3 months. One-year survival rate was 40.0%. In group B, 59 patients could be evaluated. The response rates were 40.68%(24/59), 63.33%(19/30) and 17.24%(5/29) in whole group, untreated patients, and retreated patients, respectively. The median duration of survival was 9 months and 1-year survival rate was 36.7%. There was no significant difference in objective response rate among all the patients and the patients with no prior treatment between the two groups ( P > 0.05, P > 0.05). However, among retreated patients, the response rate in group A was remarkably higher than that in group B ( P < 0.05). The main dose limiting toxicity was myelosuppression. Leukopenia at grade III+IV was significantly higher in the NIP arm than in the IP arm ( P < 0.05).
NIP yields a higher response rate than IP does in retreated patients, with acceptable toxicity, which can be the first line regimen in the retreatment of advanced NSCLC. IP regimen showes a similar response rate and less toxicity in initial patients, compared with NIP regimen, so it might be considered a relevant regimen in initial patients with advanced NSCLC.
观察去甲长春花碱（NVB）联合异环磷酰胺（IFO）和顺铂（DDP）（NIP方案）与IFO加DDP（IP方案）治疗晚期非小细胞肺癌（NSCLC）的疗效和安全性。
120例经病理证实的晚期NSCLC患者随机分为A组（NIP方案，n = 60）和B组（IP方案，n = 60）。
A组58例可评价。全组、初治患者和复治患者的有效率分别为58.62%（34/58）、65.58%（17/26）和53.12%（17/32）。中位生存期为11.3个月。1年生存率为40.0%。B组59例可评价。全组、初治患者和复治患者的有效率分别为40.68%（24/59）、63.33%（19/30）和17.24%（5/29）。中位生存期为9个月，1年生存率为36.7%。两组所有患者及未接受过治疗的患者客观缓解率差异无统计学意义（P>0.05，P>0.05）。然而，在复治患者中，A组的有效率明显高于B组（P<0.05）。主要剂量限制性毒性为骨髓抑制。NIP组III + IV级白细胞减少明显高于IP组（P<0.05）。
NIP方案在复治患者中的有效率高于IP方案，毒性可接受，可作为晚期NSCLC复治的一线方案。与NIP方案相比，IP方案在初治患者中显示出相似的有效率和较低的毒性，因此可考虑作为晚期NSCLC初治患者的相关方案。
